Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS)

Legato Capital Management LLC lessened its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 40.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 64,778 shares of the company’s stock after selling 43,769 shares during the quarter. Legato Capital Management LLC owned 0.10% of Evolus worth $715,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of EOLS. The Manufacturers Life Insurance Company grew its stake in shares of Evolus by 36.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,825 shares of the company’s stock valued at $237,000 after purchasing an additional 5,808 shares during the period. Creative Planning boosted its holdings in shares of Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after buying an additional 2,963 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Evolus by 0.9% during the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock valued at $15,480,000 after buying an additional 8,452 shares during the period. Semanteon Capital Management LP purchased a new stake in Evolus during the third quarter valued at approximately $912,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after acquiring an additional 4,780 shares during the period. Institutional investors own 90.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Tuesday, January 21st. Finally, Barclays upped their price target on Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, January 27th.

Evolus Stock Performance

Shares of NASDAQ EOLS opened at $15.04 on Friday. The stock has a market cap of $952.33 million, a PE ratio of -16.53 and a beta of 1.33. Evolus, Inc. has a 1 year low of $9.25 and a 1 year high of $17.82. The firm has a fifty day moving average price of $12.03 and a 200-day moving average price of $13.96. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.